Agilon Health (NYSE:AGL) Announces Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Agilon Health (NYSE:AGL) issued its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19), Zacks reports. Agilon Health had a negative net margin of 6.60% and a negative return on equity of 100.06%. The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.46 billion.

Here are the key takeaways from Agilon Health’s conference call:

• 2026 guidance: Management expects revenue around $5.5B (midpoint), medical margin ~$325M and adjusted EBITDA roughly breakeven at the midpoint, with platform membership targeted at 525k–540k (MA ~430k, ACO ~103k) and a net cost-trend assumption near 7%.
• Operational progress includes an enhanced data pipeline (member-level risk scoring covering >85% of members), AI-assisted Burden of Illness identification, and clinical pathways (CHF active in >90% of the network) that management says will improve risk capture, utilization and quality.
• 2025 financials were weak—full-year adjusted EBITDA of -$296M and medical margin of -$57M—driven by elevated cost trends (~6.5%) and several large inpatient claims, leading the company to exit unprofitable payer contracts and reduce MA membership (to ~430k, including ~25k on care-coordination fee arrangements).
• Liquidity and policy outlook: year-end cash of $285M (plus $91M ACO-held cash) with an extended credit facility and a plan to finish 2026 with at least $125M, while management warns the CMS Advance Notice may understate cost trends but believes its BOI/clinical initiatives can mitigate much of the risk-model impact.

Agilon Health Stock Down 6.3%

Shares of NYSE:AGL traded down $0.04 during mid-day trading on Friday, reaching $0.56. 734,751 shares of the stock were exchanged, compared to its average volume of 7,684,411. The stock’s 50 day simple moving average is $0.71 and its 200-day simple moving average is $0.86. Agilon Health has a one year low of $0.34 and a one year high of $6.08. The company has a market cap of $231.08 million, a P/E ratio of -0.58 and a beta of 0.06.

Trending Headlines about Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Q4 revenue beat estimates and the company laid out a 2026 plan that targets roughly $5.5B in revenue and breakeven adjusted EBITDA, which signals management’s path to stabilization even as it executes a transformation. Agilon health outlines $5.5B revenue and breakeven adjusted EBITDA for 2026
• Neutral Sentiment: Revenue for the quarter was $1.57B (above the $1.46B consensus), but other metrics remain weak; analysts still expect negative EPS for the year, leaving the story mixed until profitability trends become clearer. Compared to Estimates, Agilon (AGL) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: EPS missed badly — reported a ($0.46) loss vs. the ($0.27) consensus — which is driving near‑term selling pressure as the company remains unprofitable. Agilon Health Q4 results and conference call
• Negative Sentiment: Updated guidance disappointed: FY revenue guidance (~$5.4–$5.6B) and Q1 revenue guidance came in below consensus, reinforcing concerns about near‑term growth and pressuring valuation. Agilon press release / slide deck
• Negative Sentiment: Multiple law firms have filed or announced securities‑fraud class actions and are soliciting lead plaintiffs (March 2 lead‑plaintiff deadlines), increasing legal overhang and downside risk until litigation settles or is resolved. AGL Investors Have Opportunity to Lead agilon health, inc. Securities Fraud Lawsuit (Schall Law Firm)

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research reiterated a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a report on Wednesday, January 21st. Royal Bank Of Canada raised Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Finally, Barclays decreased their price objective on Agilon Health from $1.00 to $0.50 and set an “underweight” rating for the company in a research report on Friday. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $2.55.

Hedge Funds Weigh In On Agilon Health

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in Agilon Health by 196.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock valued at $13,812,000 after purchasing an additional 13,283,930 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Agilon Health by 1,346.6% during the 4th quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company’s stock worth $7,033,000 after buying an additional 9,505,837 shares during the last quarter. Voleon Capital Management LP grew its holdings in shares of Agilon Health by 5,519.2% in the 3rd quarter. Voleon Capital Management LP now owns 2,741,039 shares of the company’s stock valued at $2,823,000 after acquiring an additional 2,692,259 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Agilon Health by 280.4% in the 3rd quarter. Millennium Management LLC now owns 2,998,838 shares of the company’s stock valued at $3,089,000 after acquiring an additional 2,210,568 shares in the last quarter. Finally, Amundi acquired a new stake in shares of Agilon Health in the fourth quarter valued at about $1,356,000.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.